We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$7.44B
AUM Growth
+$696M
Cap. Flow
+$295M
Cap. Flow %
3.96%
Top 10 Hldgs %
25.63%
Holding
169
New
15
Increased
63
Reduced
24
Closed
17

Top Buys

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$57.2M
2
NCNO icon
nCino
NCNO
+$41.7M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$35.5M
4
ARGX icon
argenx
ARGX
+$33.8M
5
SHLS icon
Shoals Technologies Group
SHLS
+$31.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$52M
2
VRSK icon
Verisk Analytics
VRSK
+$37.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$26.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.1M
5
OKTA icon
Okta
OKTA
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 35.75%
2 Technology 29.25%
3 Industrials 12.31%
4 Consumer Discretionary 7.52%
5 Communication Services 5.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
101
Xencor
XNCR
$1.59B
$17.5M 0.23%
506,000
– –
CIEN icon
102
Ciena
CIEN
$52.7B
$17.4M 0.23%
305,175
+17,000
+6% +$937K
PLD icon
103
Prologis
PLD
$136B
$16.5M 0.22%
138,200
+15,156
+12% +$1.77M
KALV
104
DELISTED
KalVista Pharmaceuticals
KALV
$15.9M 0.21%
665,681
-707,319
-52% -$18.5M
ORIC icon
105
Oric Pharmaceuticals
ORIC
$1.2B
$15.5M 0.21%
876,948
+446,948
+104% +$9.79M
KURA icon
106
Kura Oncology
KURA
$826M
$14.7M 0.2%
704,000
-913,573
-56% -$22.7M
PNR icon
107
Pentair
PNR
$10.6B
$14.3M 0.19%
211,200
+32,500
+18% +$2.15M
EQIX icon
108
Equinix
EQIX
$103B
$14.2M 0.19%
+17,693
New +$13.1M
KLAC icon
109
KLA
KLAC
$236B
$13.4M 0.18%
413,980
+56,000
+16% +$1.79M
FHN icon
110
First Horizon
FHN
$12.1B
$13.3M 0.18%
771,000
-97,800
-11% -$1.78M
MASS icon
111
908 Devices
MASS
$313M
$12.9M 0.17%
333,283
– –
SNDX icon
112
Syndax Pharmaceuticals
SNDX
$1.73B
$12.1M 0.16%
702,348
-1,314,645
-65% -$24.1M
SPRY icon
113
ARS Pharmaceuticals
SPRY
$559M
$11.5M 0.15%
371,384
– –
SNPS icon
114
Synopsys
SNPS
$71.3B
$11.2M 0.15%
40,757
+12,800
+46% +$3.25M
SBAC icon
115
SBA Communications
SBAC
$19.3B
$11M 0.15%
34,600
+11,834
+52% +$3.55M
IEX icon
116
IDEX
IEX
$17.3B
$10.1M 0.14%
45,700
+8,000
+21% +$1.77M
PHVS icon
117
Pharvaris
PHVS
$2.37B
$9.84M 0.13%
541,563
+41,563
+8% +$943K
SNV
118
DELISTED
Synovus
SNV
$9.66M 0.13%
220,200
-45,700
-17% -$2.15M
ELS icon
119
Equity Lifestyle Properties
ELS
$12.7B
$9.45M 0.13%
127,200
+31,900
+33% +$2.26M
AESC
120
DELISTED
The AES Corporation
AESC
$8.95M 0.12%
+83,200
New +$8.8M
BOLT icon
121
Bolt Biotherapeutics
BOLT
$7.47M
$8.26M 0.11%
26,700
+10,553
+65% +$4.28M
DSGN icon
122
Design Therapeutics
DSGN
$788M
$7.96M 0.11%
400,000
– –
VFC icon
123
VF Corp
VFC
$5.87B
$7.79M 0.1%
95,000
+13,400
+16% +$1.12M
APTO
124
DELISTED
Aptose Biosciences, Inc.
APTO
$7.63M 0.1%
5,109
– –
AWK icon
125
American Water Works
AWK
$26.7B
$7.54M 0.1%
48,900
+5,800
+13% +$904K
3 4
5
6 7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Eventide Asset Management held 169 positions worth $7.44B, up 10% from $6.75B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $295M of net new capital in Q2 2021, opening 15 new positions and adding to 63 existing holdings. Its largest new stake was nCino: 662,500 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 40% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Verisk Analytics, an estimated $37.6M trimmed.

  • Eventide Asset Management's largest Q2 2021 buy was nCino: 662,500 shares worth $39.7M.
  • Eventide Asset Management added most to Zymeworks in Q2 2021, an estimated $57.2M increase.
  • Eventide Asset Management's biggest Q2 2021 reduction was Verisk Analytics, cutting an estimated $37.6M.
  • Eventide Asset Management fully exited Sarepta Therapeutics in Q2 2021, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $7.44B portfolio in Q2 2021.
  • Eventide Asset Management opened 15 new positions and closed 17 in Q2 2021.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $7.44B.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.